share_log

Wells Fargo Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $9

Benzinga ·  Oct 23 22:24  · Ratings

Wells Fargo analyst Yanan Zhu maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and lowers the price target from $27 to $9.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment